Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the recipient of some unusual options trading on Thursday. Traders bought 4,319 call options on the stock. This represents an increase of 107% compared to the typical daily volume of 2,091 call options.
Aurinia Pharmaceuticals Trading Down 1.0 %
Aurinia Pharmaceuticals stock opened at $6.91 on Friday. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.24. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82. The stock has a market capitalization of $985.81 million, a PE ratio of -16.07 and a beta of 1.44. The firm has a 50 day simple moving average of $5.88 and a 200-day simple moving average of $5.51.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The firm had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. During the same period last year, the company posted ($0.08) EPS. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. As a group, equities research analysts expect that Aurinia Pharmaceuticals will post 0.13 EPS for the current fiscal year.
Insider Activity at Aurinia Pharmaceuticals
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Stonepine Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the second quarter valued at approximately $1,713,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $84,000. Algert Global LLC grew its holdings in shares of Aurinia Pharmaceuticals by 106.8% in the 2nd quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock worth $1,107,000 after acquiring an additional 100,104 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Aurinia Pharmaceuticals by 10.0% during the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock worth $301,000 after purchasing an additional 4,808 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the second quarter valued at $1,155,000. Institutional investors own 36.83% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Emerging Markets: What They Are and Why They Matter
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Recession or Not, These 3 Stocks Are Winners
- How to Calculate Stock Profit
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.